Equites Radar

COR · Cencora, Inc.

Medical DistributionUnited StatesAnalyst view: Buy

$311.15

+2.71% last session

End-of-day data · updated 2026-07-29

Neutral2 bullish · 2 bearish technical signals
Consensus: Buy (1.57 from 12 analysts)
To mean target: +14.4%

Market cap

$62B

Enterprise value

$74B

Trailing P/E

23.9

Forward P/E

16.1

Dividend yield

1.0%

Beta

0.58

Avg volume

2M

Employees

47K

2D change

2.71%

5D change

3.13%

10D change

3.79%

30D change

13.47%

60D change

18.64%

MTD change

10.80%

YTD change

-5.00%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)1.57
Covering analysts12
Mean price target$355.83
Low price target$310.00
Upside to mean target+14.4%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)68.8
50-day MA$284.34
200-day MA$323.67
Price vs 50-day MA+12.4%
Price vs 200-day MA-1.3%
MACD histogram0.65
Volume vs 3-month avg0.6×
52w low $252.1652w high $373.25

Analyst sentiment over time — COR

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-06-24

Latest call per bank · past 12 months

Bank of America

Neutral

$285

-8.4% vs price
▲ raised from $280Maintains · 2026-06-24

Barclays

Overweight

$350

+12.5% vs price
▼ cut from $425Maintains · 2026-06-10

Wells Fargo

Overweight

$331

+6.4% vs price
▼ cut from $429Maintains · 2026-05-11

UBS

Buy

$412

+32.4% vs price
▲ raised from $410Maintains · 2026-05-07

Citigroup

Buy

$355

+14.1% vs price
▼ cut from $405Maintains · 2026-05-07

JP Morgan

Overweight

$419

+34.7% vs price
▲ raised from $417Maintains · 2026-02-10

Morgan Stanley

Overweight

$400

+28.6% vs price
▲ raised from $361Upgrade · 2026-01-29

Jefferies

Buy

$440

+41.4% vs price
▲ raised from $330Upgrade · 2026-01-22

Recent rating actions

DateFirmActionRatingPrice target
2026-06-24Bank of AmericaMaintainsNeutral$280 $285
2026-06-10BarclaysMaintainsOverweight$425 $350
2026-05-11Wells FargoMaintainsOverweight$429 $331
2026-05-07UBSMaintainsBuy$410 $412
2026-05-07CitigroupMaintainsBuy$405 $355
2026-05-07Evercore ISI GroupMaintainsOutperform$360 $300
2026-05-07BairdMaintainsOutperform$420 $339
2026-04-28William BlairInitiatesMarket Perform$0.00

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

  • RSI (14): RSI is 69 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 12.4% above the 50-day MA ($284.34).
  • Price vs 200-day MA: Trading 1.3% below the 200-day MA ($323.67).
  • MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
  • MACD (12,26,9): MACD histogram is positive (+0.65) — short-term momentum is improving.
  • 52-week range: Price sits between the 52-week low ($252.16) and high ($373.25).

COR Price Chart

Loading chart for COR

Fundamentals

Revenue (TTM)$329B
EBITDA$5.0B
Free cash flow$0M
Operating cash flow$2.0B
Book value / share$17.46
Net debt / EBITDA2.4
WACC8.0%
Revenue growth4.00%
Earnings growth128.00%

About Cencora, Inc.

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

More in Medical Distribution

Screen COR against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.